Mind Medicine (MindMed) Future Growth
Future criteria checks 0/6
Mind Medicine (MindMed) is forecast to grow earnings and revenue by 39% and 72.6% per annum respectively. EPS is expected to grow by 44.6% per annum. Return on equity is forecast to be -70.7% in 3 years.
Key information
39.0%
Earnings growth rate
44.6%
EPS growth rate
Pharmaceuticals earnings growth | 22.8% |
Revenue growth rate | 72.6% |
Future return on equity | -70.7% |
Analyst coverage | Good |
Last updated | 15 Apr 2024 |
Recent future growth updates
Recent updates
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Apr 04Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Feb 02Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
May 23We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely
Feb 07MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics
Oct 19MindMed announces proposed public offering of common shares
Sep 27MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances
Sep 20MindMed regains compliance with Nasdaq's minimum bid price listing requirement
Sep 14MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value
Sep 04Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
Aug 26Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder
Aug 24MindMed soars 71% as it appears to be following in Bed Bath & Beyond's footsteps
Aug 18Mind Medicine GAAP EPS of -$0.04 beats by $0.01
Aug 11Mind Medicine announces 1-for-15 reverse stock split
Aug 04MindMed: Another Psychedelic Medicine Play Trading At A Potential Discount
Jul 12Mind Medicine: It's Best To Stay Far Away From This Risky Psychedelic Stock
Apr 20MindMed: Falling Uncontrollably
Jan 27Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3 | -121 | -119 | -107 | 6 |
12/31/2025 | N/A | -106 | -85 | -75 | 7 |
12/31/2024 | N/A | -95 | -70 | -66 | 8 |
12/31/2023 | N/A | -96 | -64 | -64 | N/A |
9/30/2023 | N/A | -77 | -57 | -57 | N/A |
6/30/2023 | N/A | -75 | -49 | -49 | N/A |
3/31/2023 | N/A | -63 | -51 | -51 | N/A |
12/31/2022 | N/A | -57 | -50 | -50 | N/A |
9/30/2022 | N/A | -69 | -45 | -45 | N/A |
6/30/2022 | N/A | -69 | -53 | -53 | N/A |
3/31/2022 | N/A | -98 | -49 | -49 | N/A |
12/31/2021 | N/A | -93 | -46 | -46 | N/A |
9/30/2021 | N/A | -89 | -45 | -45 | N/A |
6/30/2021 | N/A | -80 | -34 | -34 | N/A |
3/31/2021 | N/A | -41 | -29 | -29 | N/A |
12/31/2020 | N/A | -34 | -24 | -24 | N/A |
9/30/2020 | N/A | -29 | -22 | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MNMD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MNMD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MNMD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MNMD is forecast to have no revenue next year.
High Growth Revenue: MNMD is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MNMD is forecast to be unprofitable in 3 years.